These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 9394746)

  • 1. Lansoprazole, H. pylori, and atrophic gastritis.
    Kuipers EJ; Klinkenberg-Knol EC; Festen HP; Meuwissen SG
    Gastroenterology; 1997 Dec; 113(6):2018-9. PubMed ID: 9394746
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recent topics on important drugs for H. pylori eradication: Lansoprazole].
    Fukuda Y; Tomita T; Koizuka H; Aoyama N
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():338-49. PubMed ID: 16363557
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicobacter pylori eradication in functional dyspepsia: new evidence for symptomatic benefit.
    Malfertheiner P
    Eur J Gastroenterol Hepatol; 2001 Aug; 13 Suppl 2():S9-11. PubMed ID: 11686231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reflux esophagitis; is the preventive eradication of Helicobacter pylori needed in patients on omeprazole?].
    Kuipers EJ; Klinkenberg-Knol EC; Festen HP; Meuwissen SG
    Ned Tijdschr Geneeskd; 1998 Apr; 142(16):883-5. PubMed ID: 9623181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Proton pump inhibitor for ulcer therapy. Tolerance profile of lansoprazole].
    Müller P; Fuchs W; Peifer-Weiss A; Simon B
    Fortschr Med; 1998 Oct; 116(28):31-2. PubMed ID: 9844264
    [No Abstract]   [Full Text] [Related]  

  • 7. [Reflux esophagitis].
    Mitsunaga A; Matsumoto R; Hoshino Y; Nakamura S; Murata Y; Oi I; Hayashi N
    Nihon Rinsho; 2002 Aug; 60(8):1559-65. PubMed ID: 12187751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bactericidal activity of lansoprazole and omeprazole against Helicobacter pylori in vitro.
    Vogt K; Hahn H
    Arzneimittelforschung; 1998 Jun; 48(6):694-7. PubMed ID: 9689430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: the long-term use of proton-pump inhibitors.
    Raghunath AS; O'Morain C; McLoughlin RC
    Aliment Pharmacol Ther; 2005 Aug; 22 Suppl 1():55-63. PubMed ID: 16042660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitors and H. pylori infection: why the concern?
    Weinstein WM
    Curr Gastroenterol Rep; 1999 Dec; 1(6):507-10. PubMed ID: 10980994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
    Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
    Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors.
    Pérez Pimiento AJ; Prieto Lastra L; Rodríguez Cabreros MI; González Sánchez LA; Mosquera MR; Cubero AG
    J Allergy Clin Immunol; 2006 Mar; 117(3):707-8. PubMed ID: 16522476
    [No Abstract]   [Full Text] [Related]  

  • 13. The early effect of proton pump inhibitor therapy on the accuracy of the 13C-urea breath test.
    Mana F; Van Laer W; Bossuyt A; Urbain D
    Dig Liver Dis; 2005 Jan; 37(1):28-32. PubMed ID: 15702856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allergy to lansoprazole: study of cross-reactivity among proton-pump inhibitors.
    Porcel S; Rodríguez A; Jiménez S; Alvarado M; Hernández J
    Allergy; 2005 Aug; 60(8):1087-8. PubMed ID: 15969693
    [No Abstract]   [Full Text] [Related]  

  • 15. Attempt to reverse atrophic gastritis associated with common variable immunodeficiency.
    Misbah SA; Chapel HM; Johnston BJ; Ali MH; Reed PI; O'Sullivan D
    J Clin Gastroenterol; 1992 Dec; 15(4):354-5. PubMed ID: 1294647
    [No Abstract]   [Full Text] [Related]  

  • 16. [H. pylori motility analysis].
    Suzuki H; Kurabayashi K; Hibi T
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():209-12. PubMed ID: 16363533
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety profile of the proton-pump inhibitors.
    Reilly JP
    Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S11-7. PubMed ID: 10597119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe erythrodermic reactions to the proton pump inhibitors omeprazole and lansoprazole.
    Cockayne SE; Glet RJ; Gawkrodger DJ; McDonagh AJ
    Br J Dermatol; 1999 Jul; 141(1):173-5. PubMed ID: 10417548
    [No Abstract]   [Full Text] [Related]  

  • 19. [Gastritis due to Helicobacter pylori].
    Haruma K
    Nihon Naika Gakkai Zasshi; 1998 May; 87(5):826-31. PubMed ID: 9648432
    [No Abstract]   [Full Text] [Related]  

  • 20. Omeprazole and accelerated onset of atrophic gastritis.
    McColl KE; Murray LS; Gillen D
    Gastroenterology; 2000 Jan; 118(1):239. PubMed ID: 10644181
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.